{"id":483210,"date":"2020-05-07T23:00:02","date_gmt":"2020-05-07T23:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=483210"},"modified":"2020-05-07T23:00:02","modified_gmt":"2020-05-07T23:00:02","slug":"anemia-in-chronic-kidney-disease-pipeline-insights-emerging-therapies-impact-the-market-outlook","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/anemia-in-chronic-kidney-disease-pipeline-insights-emerging-therapies-impact-the-market-outlook_483210.html","title":{"rendered":"Anemia In Chronic Kidney Disease Pipeline Insights: Emerging therapies impact the market outlook"},"content":{"rendered":"
\"Anemia<\/a><\/p>\n
\n
Anemia In Chronic Kidney Disease Pipeline<\/div>\n<\/div>\n<\/div>\n
Several key players such as Akebia Therapeutics, GlaxoSmithKline, Astellas Pharma, FibroGen, Inc and many others are working on developing therapies for the treatment of Anemia in Chronic Kidney Disease. The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period.<\/div>\n

“Anemia In Chronic Kidney Disease Pipeline Insight, 2020<\/a><\/strong>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Anemia In Chronic Kidney Disease market.<\/p>\n

Anemia is a frequent complication of chronic kidney disease (CKD) and it is associated with a decrease in the quality of life of patients, it causes an increase in morbidity and mortality and accelerates the rate of progression of CKD.<\/p>\n

A detailed picture of the Anemia In Chronic Kidney Disease pipeline landscape is provided, which includes the disease overview and Anemia In Chronic Kidney Disease treatment guidelines.<\/p>\n

The assessment part of the report embraces in-depth Anemia In Chronic Kidney Disease commercial assessment and clinical assessment of the Anemia In Chronic Kidney Disease pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anemia In Chronic Kidney Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Anemia In Chronic Kidney Disease market: Pipeline<\/strong><\/p>\n

DelveInsight estimates an increase in market size, a direct consequence of increasing prevalent population of Anemia in Chronic Kidney Disease patients in the 7MM.<\/p>\n

Expected launch of Vadadustat, Daprodustat shall fuel the growth of the market during the forecast period, i.e., 2020–2030. Several key players such as Akebia Therapeutics, GlaxoSmithKline, Astellas Pharma, FibroGen, Inc and many others are working on developing therapies for treatment of Anemia in Chronic Kidney Disease. The market size shall grow during the forecast period owing to the launch of upcoming therapies. The market size is expected to increase at a CAGR of XX during the study period.<\/p>\n

Request for sample pages.<\/a> <\/strong><\/p>\n

Scope of the report <\/strong><\/p>\n